Related Experiment Video

Updated: Mar 25, 2026

Assaying Protein Kinase Activity with Radiolabeled ATP
08:05

Assaying Protein Kinase Activity with Radiolabeled ATP

Published on: May 26, 2017

19.5K

Wip1 phosphatase: between p53 and MAPK kinases pathways

Anastasia R Goloudina1, Elena Y Kochetkova2, Tatyana V Pospelova2

  • 1INSERM UMR 866, University of Burgundy, Dijon, France.

Oncotarget
|February 18, 2016
PubMed

Insights

Wild type p53-induced phosphatase (Wip1) regulates tumor suppressor pathways critical for cancer therapy. Targeting Wip1 activity offers a promising strategy for enhancing anti-cancer treatments by modulating p53 and p38MAPK signaling.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Tumorigenesis involves inactivation of critical tumor suppressor pathways.
  • The p53 and p38MAPK pathways are central to cell cycle control, senescence, and apoptosis.
  • These pathways are crucial in determining tumor cell sensitivity to anti-cancer therapies.

Purpose of the Study:

  • To review the role of Wild type p53-induced phosphatase (Wip1) in tumorigenesis.
  • To explore Wip1's regulation of p53 and p38MAPK pathways.
  • To propose future directions for Wip1-targeted anti-cancer strategies.

Main Methods:

  • Literature review of in vitro and in vivo studies.
  • Analysis of genetically modified animal models.
  • Examination of Wip1's interactions with tumorigenesis pathways.

Main Results:

  • Wip1 plays a significant role in tumorigenesis by regulating p53 and p38MAPK pathways.
  • Wip1 activity directly impacts cell cycle, senescence, and cell death.
  • Wip1 manipulation strategies show potential for anti-cancer therapy.

Conclusions:

  • Wip1 is a key regulator in cancer development through its control of p53 and p38MAPK.
  • Targeting Wip1 activity is a viable strategy for novel anti-cancer treatments.
  • Further research using advanced tools is recommended to explore Wip1 interactions and therapeutic applications.
Keywords:
chemotherapyp53phosphatasetumor suppressor

More Related Videos

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay12:26

Identification of Cyclin-dependent Kinase 1 Specific Phosphorylation Sites by an In Vitro Kinase Assay

Published on: May 3, 2018

19.4K
Purification of Ubiquitinated p53 Proteins from Mammalian Cells10:55

Purification of Ubiquitinated p53 Proteins from Mammalian Cells

Published on: March 21, 2022

2.9K

Related Concept Videos

Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
7.9K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
9.2K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
6.2K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
13.8K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.4K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K